1993, the company began to produce live attenuated hepatitis A vaccine, becoming the first flagship product.
1994 rabies vaccine workshop and hepatitis a vaccine workshop were put into production;
1994165438+1October 18, Changsheng Building was completed, the company officially entered the development zone, and the external image of Changsheng began to be established;
1995 rabies vaccine production and vaccine production workshop expansion;
1997, the trademark "Wanxin" was officially registered, and Changsheng had its own brand;
1997 invested in the construction of a hepatitis A vaccine production workshop to expand the production scale;
Development of 1999 inactivated influenza vaccine;
In 2000, human rabies vaccine (Vero cells) was officially listed in China for the first time;
June 65438+1October 65438+June 2000, three products passed SDA GMP certification at one time;
In June 5438+February 2000, he was awarded the GMP certificate of National Medical Products Administration;
200 1 Cooperate with Hopkins University to develop AIDS vaccine;
In March 2002, the company cooperated with Peking University to develop "therapeutic and preventive DNA vaccine for hepatitis B";
In 2002, "Production of Inactivated Influenza Vaccine by Sepharose4FF Column Chromatography" won the gold medal in Geneva International Patent and Technology Achievements Expo;
On September 29th, 2003, "Wanxin human rabies vaccine (Vero cell)" was awarded as "National User Satisfaction Product" by china association for quality and the National User Committee.
On June 5438+February 65438+July 2003, "Wanxin" was recognized as "Changchun Famous Trademark" by the Changchun Municipal People's Government.
In 2003, the company's products began to export;
In 2004, the technical transformation project of rabies vaccine high-tech products; The first batch of high-tech industrialization projects for the development of high-tech industries in the old industrial base in Northeast China; Eight projects, such as the "2004 National Innovation Fund Project for Small and Medium-sized Sci-tech Enterprises" of influenza split vaccine, have been approved by the state and local governments and received financial support.
In 2005, the technology of purifying influenza vaccine by column chromatography was authorized by the national invention patent;
In 2005, the split vaccine project won the first prize of Changchun science and technology progress;
On June 5438+ 10, 2006, all production workshops passed the national SDA GMP certification for re-inspection;
In April 2007, Changchun Changsheng Institute of Biology and Life Sciences was formally established.
In September 2009, the application for registration of influenza A vaccine H 1N 1 has been officially approved by the State Food and Drug Administration of the United States, and it is the first split influenza A vaccine H 1N 1 approved for production in Jilin Province.